Investigators observed early adoption of the trastuzumab biosimilar Kanjinti in patients with early breast cancer and metastatic breast cancer.
Early adoption of the trastuzumab biosimilar Kanjinti was high among patients with breast cancer whether or not they had prior use of the originator (Herceptin), investigators said in a poster presentation at the National Comprehensive Cancer Network (NCCN) Virtual Annual Conference 2021.
Investigators set out to measure how quickly patients with a breast cancer diagnosis were started on the biosimilar during the agent’s first year of availability. Kanjinti, an Amgen product, was launched in July 2019. They used Flatiron Health retrospective data to develop 2 patient cohorts: those with early breast cancer (eBC, n = 2149) and those with metastatic breast cancer (mBC, n = 799). Those cohorts were further subdivided into patients with prior reference product (RP) exposure and no RP exposure.
Investigators said that among trastuzumab-naïve patients, the median time from diagnosis of eBC to initiation of biosimilar trastuzumab was 34 days; the respective time for those with a diagnosis of mBC was 30 days.
Among patients with prior RP exposure, 81% of patients with eBC transitioned and 75% with mBC transitioned to the biosimilar within 28 days of the final administration of RP. “Use of [Kanjinti] was observed in both RP-naïve and prior RP-treated patients, with evidence showing comparable patient characteristics between the 2 groups,” investigators wrote (Table).
The investigators found that the first providers began to employ the trastuzumab biosimilar soon after it was launched—within 4 and 12 days of market entry. In the United States, Kanjinti was the first trastuzumab biosimilar to be launched, although it was not the first trastuzumab biosimilar to be approved by the FDA.
The study did not evaluate for reasons why patients previously treated with RP were transitioned to the biosimilar, owing to a lack of appropriate data, investigators said.
Reference
Jin R, Accortt NA, Sandschafer D, Lawrence T, Mahtani RL. Characteristics of breast cancer patients treated with trastuzumab-anns, a trastuzumab biosimilar, in a real-world setting. Poster presented at: NCCN Virtual Annual Conference 2021; March 18-22, 2021. Accessed March 18, 2021. https://www.nccn.org/professionals/meetings/annual_conference_2021.aspx
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.